SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

Fulcrum Therapeutics Q1 EPS $(0.810) Misses $(0.750) Estimate, Sales $750.000K

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.810) per share which missed the analyst consensus estimate of $(0.750) by 8 percent. The company reported $750.000 thousand in sales this quarter.

Benzinga · 05/13/2020 11:12

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.810) per share which missed the analyst consensus estimate of $(0.750) by 8 percent. The company reported $750.000 thousand in sales this quarter.